Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels

Journal of Clinical Neurology (Korea)

Volumn 9, Issue 1, 2013, Pages 36-42

  Kim, Su Hyun ^a   Kim, Woojun ^a   Huh, So Young ^a   Lee, Kyue Yim ^a   Jung, In Ja ^a   Kim, Ho Jin ^a  

^a National Cancer Center   (South Korea)

Author keywords

Anti aquaporin 4 antibody; Neuromyelitis optica; Plasmapheresis

Indexed keywords

EID: 84877822773     PISSN: 17386586     EISSN: 20055013     Source Type: Journal    
DOI: 10.3988/jcn.2013.9.1.36     Document Type: Article

References (25)

1. Lehmann HC, Hartung HP, Hetzel GR, Stüve O, Kieseier BC. Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 2006;63:930-935.
2. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
3. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010;133:349-361.
4. Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006;59:566-569.
5. Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Winger-chuk DM, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008;70:2197-2200.
6. Bennett JL, Lam C, Kalluri SR, Saikali P, Bautista K, Dupree C, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009;66:617-629.
7. Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, et al. Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;66:630-643.
8. Kim W, Kim SH, Kim HJ. New insights into neuromyelitis optica. J Clin Neurol 2011;7:115-127.
9. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: Predictors of response. Neurology 2002;58:143-146.
10. Llufriu S, Castillo J, Blanco Y, Ramió-Torrentà L, Río J, Vallès M, et al. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology 2009;73:949-953.
11. Magaña SM, Keegan BM, Weinshenker BG, Erickson BJ, Pittock SJ, Lennon VA, et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 2011;68:870-878.
12. Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, Fujihara K, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007;13:128-132.
13. Wang KC, Wang SJ, Lee CL, Chen SY, Tsai CP. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci 2011;18:43-46.
14. Collongues N, de Seze J. Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord 2011;4:111-121.
15. Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010;17:1019-1032.
16. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linen-berger ML, Marques MB, et al. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010;25:83-177.
17. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenk-er BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
18. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6: 805-815.
19. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-1114.
20. Kim W, Lee JE, Li XF, Kim SH, Han BG, Lee BI, et al. Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. Mult Scler 2012;18:578-586.
21. Narita YM, Hirahara K, Mizukawa Y, Kano Y, Shiohara T. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: Is cytokine expression analysis useful in predicting its therapeutic efficacy? J Dermatol 2011;38:236-245.
22. Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 2009;15:487-492.
23. Brecher ME. Plasma exchange: why we do what we do. J Clin Apher 2002;17:207-211.
24. Bonnan M, Cabre P. Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int 2012;2012:787630.
25. Okafor C, Ward DM, Mokrzycki MH, Weinstein R, Clark P, Balogun RA. Introduction and overview of therapeutic apheresis. J Clin Apher 2010;25:240-249.